BioPharmSignal logoBioPharmSignal

Biotech News

NGM Bio to Participate in the Cowen 44th Annual Health Care Conference

NGM Biopharmaceuticals (NGM)NGM BiopharmaceuticalsConference / presentation

SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will

Related news

CMPXCompass Therapeutics2026-07-17 14:42 EST

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026

ZNTLZentalis2026-07-17 20:15 EST

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

LYELLyell Immunopharma2026-06-25 12:00 EST

Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

RVMDRevolution Medicines2026-06-24 23:31 EST

Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

COGTCogent Biosciences2026-06-12 12:01 EST

Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress

REGNRegeneron Pharmaceuticals2026-08-19 20:05 EST

Regeneron Announces Investor Conference Presentations

KURAKura Oncology2026-07-14 11:02 EST

Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026

FATEFate Therapeutics2026-07-01 20:05 EST

Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences

FATEFate Therapeutics2026-08-14 11:00 EST

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

KYMRKymera2026-06-24 20:01 EST

Kymera Therapeutics Appoints Felix J. Baker, Ph.D., as Chairman of the Board of Directors

View all latest news

NGM Biopharmaceuticals

NGM Biopharmaceuticals is a biotech company focused on metabolic, liver, and oncology programs. Its business has been shaped by a broad platform approach and ongoing portfolio decisions.

Recent company news

NGMNGM Biopharmaceuticals2025-02-24 08:00 EST

NGM Bio Announces First Participant Dosed in EMERALD Phase 2 Clinical Study of NGM120 for the Treatment of Hyperemesis Gravidarum (HG) in Pregnant Patients

NGMNGM Biopharmaceuticals2025-02-04 12:00 EST

NGM Bio Announces Appointment of Wendy Yeh, M.D. as Chief Medical Officer

NGMNGM Biopharmaceuticals2024-12-19 12:01 EST

NGM Bio and KdT Ventures Enter into Worldwide License Agreement for NGM313, a Phase 2-ready FGFR1c/β-Klotho Agonist Drug Candidate

NGMNGM Biopharmaceuticals2024-07-17 11:01 EST

NGM Bio Announces $122 Million Series A Financing to Initiate Registrational Trial in Primary Sclerosing Cholangitis and Fund Phase 2 Trial in Hyperemesis Gravidarum

NGMNGM Biopharmaceuticals2024-04-05 13:20 EST

NGM Bio Announces Closing of Tender Offer

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States